Background: Follicular bronchiolitis (FB) is an uncommon but important pulmonary manifestation in children.
Methods: In this report, we present the clinical presentations and histopathological data of an 8-year-old boy with FB.
Results: The patient had a history of recurrent cough and dyspnea for 5 years with progressive worsening of symptoms. An initial pulmonary function test showed an obstructive ventilatory defect. Chest X-ray demonstrated miliary nodules. High-resolution computed tomography showed reticulonodular opacification and central consolidation. Histopathological examination revealed that lymphoid follicles with reactive germinal centers distributed along the bronchioles. The boy responded favorably to corticosteroid therapy and recovered well.
Conclusions: Diagnosis of FB should be considered when a child presents with chronic bronchial obstruction. Open lung biopsy is necessary for confirmation of the diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12519-011-0277-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare interstitial lung diseases: a narrative review.
J Thorac Dis
September 2024
Division of Respirology and Sleep Medicine, Queen's University, Kingston, ON, Canada.
Article Synopsis
- Interstitial lung diseases (ILDs) include over 200 types, with a growing focus on fibrosing lung diseases due to new therapies, but less common ILDs also need attention because of their poor prognosis.
- This review provides an updated overview of rare ILDs, including idiopathic interstitial pneumonias, genetic disorders like Hermansky-Pudlak syndrome, and conditions associated with lymphoid tissue proliferation, such as follicular bronchiolitis.
- Despite their rarity, improved recognition of imaging and pathology is enhancing our understanding, but these ILDs still pose diagnostic challenges and lack established treatments, highlighting the need for more research.
Diffuse Cystic Lung Disease: A Clinical Guide to Recognition and Management.
Chest
August 2024
Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland. Electronic address:
Topic Importance: Diffuse cystic lung diseases (DCLDs) represent a group of pathophysiologically heterogeneous entities that share a common radiologic phenotype of multiple thin-walled pulmonary cysts. DCLDs differ from the typical fibroinflammatory interstitial lung diseases in their epidemiology, clinical presentation, molecular pathogenesis, and therapeutic approaches, making them worthy of a distinct classification. The importance of timely and accurate identification of DCLDs is heightened by the impact on patient management including recent discoveries of targeted therapeutic approaches for some disorders.
View Article and Find Full Text PDFConcomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease.
Front Immunol
April 2024
First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Article Synopsis
- Defective IL-2 production is linked to immune issues in systemic lupus erythematosus (SLE), and low-dose IL-2 treatment shows promise for improving regulatory T cell (Treg) numbers.
- The study aimed to see if adding IL-2 could maintain Treg levels during treatment with calcineurin inhibitors, using a murine model of SLE.
- Results revealed that combining IL-2 with tacrolimus improved kidney function and delayed disease symptoms more effectively than using either treatment alone, suggesting a potential benefit for treating lupus nephritis.
Persistent and fatal severe acute respiratory syndrome coronavirus 2 infection in a patient with severe hypogammaglobulinemia: a case report.
J Med Case Rep
May 2023
Departamento de Medicina Interna, Unidad de Reumatología, Universidad Icesi, Facultad de Ciencias de la Salud, 760031, Cali, Colombia.
Background: Viruses are constantly changing as a result of mutations, and new viral variants are expected to appear over time. The virus that causes coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, is not excluded from this condition. Patients with some types of immunodeficiency have been reported to experience symptoms that vary from mild to severe, or even death, after being infected with severe acute respiratory syndrome coronavirus 2.
View Article and Find Full Text PDFProlonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.
Viruses
March 2023
1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
A Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) led to a pandemic outbreak in 2019. COVID-19's course and its treatment in immunocompromised patients are uncertain. Furthermore, there is a possibility of protracted SARS-CoV-2 infection and the need for repeated antiviral treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!